Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists

A compound of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof:

• wherein:
• R1 is H or C1-6 alkyl;
• R2 is aryl or C3-7 cycloalkyl or heteroaryl;
• R3 is H or C1-3 alkyl, optionally substituted by one or more fluorines;
• R4 is R8R9;
• R8 is a single bond, C1-6 alkyl, or aryl;
• R9 is H, COO R10, or NR11R12;
• R10 is H or C1-6 alkyl;
• R11 and R12 are independently selected from H and C1-6 alkyl, or are joined to form a 5-7 membered heterocyclic ring;
• R5 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, aryl, or a single or fused ring aromatic heterocyclic group;
• R6 represents H or up to three substituents independently selected from the list consisting of:
• C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- or di-C1-6 alkylamino;
• R7 is H or halo;
• a is 1-6;
• and
• any of R2, R5, R8, R10, R11 and R12 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo;
• subject to the proviso that said compound is not a compound of formula (I) wherein R7 represents H, R6 represents H, R5 represents phenyl, a is 1, and R1, R2, R3 and R4 are one of the following combinations: